The Motley Foolยท2025-09-11 08:59Group 1: Novo Nordisk - Novo Nordisk underestimated the demand for its anti-obesity treatment Wegovy at its U.S. launch in 2021, facing competition from Eli Lilly's more effective drug [3][4] - The stock has declined by 68% over the past year, but management expects operating profits to rise by 10% to 16% this year when adjusted for currency fluctuations [4] - The current price of Novo Nordisk is 13.8 times forward-looking earnings expectations, which is considered low given its double-digit annual profit growth [5] - Semaglutide, the active ingredient in Wegovy, is expected to maintain a significant market share due to its tolerability and cardiovascular benefits compared to competitors [6][7][8] - Patents for semaglutide are expected to protect it from biosimilar competition until at least 2032, and the stock offers a 3.1% dividend yield, with dividends having more than doubled since 2021 [9] Group 2: Healthpeak Properties - Despite a slowdown in funding for start-up biotechnology businesses, U.S. spending on prescription drugs increased by 11.4% in 2023, reaching $449.7 billion [10] - Healthpeak Properties is a REIT that focuses on acquiring and building laboratories for pharmaceutical and biotech companies, and it merged with Physicians Realty Trust to diversify its portfolio [12] - The merger led to a reduction in dividend payments, which is a significant concern for REIT investors [12][13] - Management expects funds from operations to reach $1.84 per share this year, with the stock priced around $18, equating to roughly 10 times this year's adjusted FFO expectation [13] - Shares of Healthpeak Properties currently offer a 6.8% dividend yield, making it an attractive option for long-term investors [14]